Myelodysplastic syndromes

Peter L. Greenberg, Eyal Attar, Minoo Battiwalla, John M. Bennett, Clara D. Bloomfield, Carlos M. DeCastro, Joachim Deeg, Harry P. Erba, James M. Foran, Guillermo Garcia-Manero, Steven D. Gore, David Head, Lori J. Maness, Michael Millenson, Stephen D. Nimer, Margaret R. O'Donnell, Hussain I. Saba, Paul J. Shami, Kathy Spiers, Richard M. StoneMartin S. Tallman, Peter Westervelt

Research output: Contribution to journalReview article

17 Citations (Scopus)

Abstract

These suggested practice guidelines are based on extensive evaluation of reviewed risk-based data and indicate useful current approaches for managing patients with MDS. The FDA recently approved 4 drugs for treating specific subtypes of MDS: lenalidomide for MDS patients with del(5q) cytogenetic, abnormalities; azacytidine and decitabine for treating higher-risk or nonresponsive MDS patients; and deferasirox for iron chelation of MDS patients with iron overload. However, because a substantial proportion of MDS patient subsets lack effective treatment for their cytopenias or for altering disease natural history, clinical trials with these and other novel therapeutic agents along with supportive care remain the hallmark of management for this disease. The role of thrombopoietic cytokines in managing thrombocytopenia in MDS requires fiirther evaluation. In addition, further determination of the effects of these therapeutic interventions on patient QOL is important.97,100,101,109,110 Progress toward improving management of MDS has occurred over the past few years and more advances are anticipated using these guidelines as a framework for coordinating comparative clinical trials.

Original languageEnglish (US)
Pages (from-to)902-925
Number of pages24
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume6
Issue number9
StatePublished - Oct 1 2008

Fingerprint

Myelodysplastic Syndromes
decitabine
Clinical Trials
Azacitidine
Iron Overload
Therapeutic Uses
Disease Management
Natural History
Practice Guidelines
Chromosome Aberrations
Thrombocytopenia
Iron
Guidelines
Cytokines
Therapeutics
Pharmaceutical Preparations

Keywords

  • Chronic myelomonocytic leukemia
  • Cytopenias
  • Myelodysplastic syndromes
  • NCCN clinical practice guidelines
  • Refractory anemia
  • Treatment

ASJC Scopus subject areas

  • Oncology

Cite this

Greenberg, P. L., Attar, E., Battiwalla, M., Bennett, J. M., Bloomfield, C. D., DeCastro, C. M., ... Westervelt, P. (2008). Myelodysplastic syndromes. JNCCN Journal of the National Comprehensive Cancer Network, 6(9), 902-925.

Myelodysplastic syndromes. / Greenberg, Peter L.; Attar, Eyal; Battiwalla, Minoo; Bennett, John M.; Bloomfield, Clara D.; DeCastro, Carlos M.; Deeg, Joachim; Erba, Harry P.; Foran, James M.; Garcia-Manero, Guillermo; Gore, Steven D.; Head, David; Maness, Lori J.; Millenson, Michael; Nimer, Stephen D.; O'Donnell, Margaret R.; Saba, Hussain I.; Shami, Paul J.; Spiers, Kathy; Stone, Richard M.; Tallman, Martin S.; Westervelt, Peter.

In: JNCCN Journal of the National Comprehensive Cancer Network, Vol. 6, No. 9, 01.10.2008, p. 902-925.

Research output: Contribution to journalReview article

Greenberg, PL, Attar, E, Battiwalla, M, Bennett, JM, Bloomfield, CD, DeCastro, CM, Deeg, J, Erba, HP, Foran, JM, Garcia-Manero, G, Gore, SD, Head, D, Maness, LJ, Millenson, M, Nimer, SD, O'Donnell, MR, Saba, HI, Shami, PJ, Spiers, K, Stone, RM, Tallman, MS & Westervelt, P 2008, 'Myelodysplastic syndromes', JNCCN Journal of the National Comprehensive Cancer Network, vol. 6, no. 9, pp. 902-925.
Greenberg PL, Attar E, Battiwalla M, Bennett JM, Bloomfield CD, DeCastro CM et al. Myelodysplastic syndromes. JNCCN Journal of the National Comprehensive Cancer Network. 2008 Oct 1;6(9):902-925.
Greenberg, Peter L. ; Attar, Eyal ; Battiwalla, Minoo ; Bennett, John M. ; Bloomfield, Clara D. ; DeCastro, Carlos M. ; Deeg, Joachim ; Erba, Harry P. ; Foran, James M. ; Garcia-Manero, Guillermo ; Gore, Steven D. ; Head, David ; Maness, Lori J. ; Millenson, Michael ; Nimer, Stephen D. ; O'Donnell, Margaret R. ; Saba, Hussain I. ; Shami, Paul J. ; Spiers, Kathy ; Stone, Richard M. ; Tallman, Martin S. ; Westervelt, Peter. / Myelodysplastic syndromes. In: JNCCN Journal of the National Comprehensive Cancer Network. 2008 ; Vol. 6, No. 9. pp. 902-925.
@article{ddca6750959e4126bf2f8011eba2023e,
title = "Myelodysplastic syndromes",
abstract = "These suggested practice guidelines are based on extensive evaluation of reviewed risk-based data and indicate useful current approaches for managing patients with MDS. The FDA recently approved 4 drugs for treating specific subtypes of MDS: lenalidomide for MDS patients with del(5q) cytogenetic, abnormalities; azacytidine and decitabine for treating higher-risk or nonresponsive MDS patients; and deferasirox for iron chelation of MDS patients with iron overload. However, because a substantial proportion of MDS patient subsets lack effective treatment for their cytopenias or for altering disease natural history, clinical trials with these and other novel therapeutic agents along with supportive care remain the hallmark of management for this disease. The role of thrombopoietic cytokines in managing thrombocytopenia in MDS requires fiirther evaluation. In addition, further determination of the effects of these therapeutic interventions on patient QOL is important.97,100,101,109,110 Progress toward improving management of MDS has occurred over the past few years and more advances are anticipated using these guidelines as a framework for coordinating comparative clinical trials.",
keywords = "Chronic myelomonocytic leukemia, Cytopenias, Myelodysplastic syndromes, NCCN clinical practice guidelines, Refractory anemia, Treatment",
author = "Greenberg, {Peter L.} and Eyal Attar and Minoo Battiwalla and Bennett, {John M.} and Bloomfield, {Clara D.} and DeCastro, {Carlos M.} and Joachim Deeg and Erba, {Harry P.} and Foran, {James M.} and Guillermo Garcia-Manero and Gore, {Steven D.} and David Head and Maness, {Lori J.} and Michael Millenson and Nimer, {Stephen D.} and O'Donnell, {Margaret R.} and Saba, {Hussain I.} and Shami, {Paul J.} and Kathy Spiers and Stone, {Richard M.} and Tallman, {Martin S.} and Peter Westervelt",
year = "2008",
month = "10",
day = "1",
language = "English (US)",
volume = "6",
pages = "902--925",
journal = "JNCCN Journal of the National Comprehensive Cancer Network",
issn = "1540-1405",
publisher = "Cold Spring Publishing LLC",
number = "9",

}

TY - JOUR

T1 - Myelodysplastic syndromes

AU - Greenberg, Peter L.

AU - Attar, Eyal

AU - Battiwalla, Minoo

AU - Bennett, John M.

AU - Bloomfield, Clara D.

AU - DeCastro, Carlos M.

AU - Deeg, Joachim

AU - Erba, Harry P.

AU - Foran, James M.

AU - Garcia-Manero, Guillermo

AU - Gore, Steven D.

AU - Head, David

AU - Maness, Lori J.

AU - Millenson, Michael

AU - Nimer, Stephen D.

AU - O'Donnell, Margaret R.

AU - Saba, Hussain I.

AU - Shami, Paul J.

AU - Spiers, Kathy

AU - Stone, Richard M.

AU - Tallman, Martin S.

AU - Westervelt, Peter

PY - 2008/10/1

Y1 - 2008/10/1

N2 - These suggested practice guidelines are based on extensive evaluation of reviewed risk-based data and indicate useful current approaches for managing patients with MDS. The FDA recently approved 4 drugs for treating specific subtypes of MDS: lenalidomide for MDS patients with del(5q) cytogenetic, abnormalities; azacytidine and decitabine for treating higher-risk or nonresponsive MDS patients; and deferasirox for iron chelation of MDS patients with iron overload. However, because a substantial proportion of MDS patient subsets lack effective treatment for their cytopenias or for altering disease natural history, clinical trials with these and other novel therapeutic agents along with supportive care remain the hallmark of management for this disease. The role of thrombopoietic cytokines in managing thrombocytopenia in MDS requires fiirther evaluation. In addition, further determination of the effects of these therapeutic interventions on patient QOL is important.97,100,101,109,110 Progress toward improving management of MDS has occurred over the past few years and more advances are anticipated using these guidelines as a framework for coordinating comparative clinical trials.

AB - These suggested practice guidelines are based on extensive evaluation of reviewed risk-based data and indicate useful current approaches for managing patients with MDS. The FDA recently approved 4 drugs for treating specific subtypes of MDS: lenalidomide for MDS patients with del(5q) cytogenetic, abnormalities; azacytidine and decitabine for treating higher-risk or nonresponsive MDS patients; and deferasirox for iron chelation of MDS patients with iron overload. However, because a substantial proportion of MDS patient subsets lack effective treatment for their cytopenias or for altering disease natural history, clinical trials with these and other novel therapeutic agents along with supportive care remain the hallmark of management for this disease. The role of thrombopoietic cytokines in managing thrombocytopenia in MDS requires fiirther evaluation. In addition, further determination of the effects of these therapeutic interventions on patient QOL is important.97,100,101,109,110 Progress toward improving management of MDS has occurred over the past few years and more advances are anticipated using these guidelines as a framework for coordinating comparative clinical trials.

KW - Chronic myelomonocytic leukemia

KW - Cytopenias

KW - Myelodysplastic syndromes

KW - NCCN clinical practice guidelines

KW - Refractory anemia

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=56049098183&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=56049098183&partnerID=8YFLogxK

M3 - Review article

C2 - 18926100

AN - SCOPUS:56049098183

VL - 6

SP - 902

EP - 925

JO - JNCCN Journal of the National Comprehensive Cancer Network

JF - JNCCN Journal of the National Comprehensive Cancer Network

SN - 1540-1405

IS - 9

ER -